Notice of Added Research Goals for RFA-DA-19-005 "Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required)"

Notice Number: NOT-DA-18-037

Key Dates
Release Date: September 04, 2018

Related Announcements
RFA-DA-19-005

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to add to the Research Goals section for RFA-DA-19-005 "Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required)".

Current Text:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Research Goals

The focus of this FOA is on improving the clinical quality of OUD care using FDA-approved medications that is provided to patients with OUD. Examples of relevant of quality improvement topics may include, but are not limited to, the following:

  • Ensuring safety and effectiveness during OUD treatment induction and stabilization.
  • Promoting long-term use of FDA-approved OUD treatment medications at effective doses as clinically appropriate.
  • Ensuring safety and continued recovery during transitions across evidence-based modalities or OUD treatment medications.
  • Ensuring safety and continued recovery among patients who choose to discontinue medications.
  • Establishing a pathway for reentry to evidence-based treatment for patients who disengaged and resume substance use.
  • Making treatment more convenient and patient-centered, including strategies that allow for patient choice of all FDA-approved medication

New Text:

The focus of this FOA is on improving the clinical quality of OUD care using FDA-approved medications that is provided to patients with OUD. Examples of relevant of quality improvement topics may include, but are not limited to, the following:

  • Ensuring safety and effectiveness during OUD treatment induction and stabilization.
  • Promoting long-term use of FDA-approved OUD treatment medications at effective doses as clinically appropriate.
  • Ensuring safety and continued recovery during transitions across evidence-based modalities or OUD treatment medications.
  • Ensuring safety and continued recovery among patients who choose to discontinue medications.
  • Establishing a pathway for reentry to evidence-based treatment for patients who disengaged and resume substance use.
  • Making treatment more convenient and patient-centered, including strategies that allow for patient choice of all FDA-approved medication
  • Pain management for individuals receiving OUD medication treatment, for example the use of non-opioid medications to treat pain, and its effect on non-medical opioid use and subsequent harms from opioids.
  • OUD medication treatment for individuals 65 years and older.

All other aspects of this Funding Opportunity Announcement remain unchanged.

Inquiries

Please direct all inquiries to:

Sarah Q. Duffy, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-451-4998
Email: duffys@nida.nih.gov